BMC acts as Bellicum’s in-house communications team, working closely with senior management. Employing a variety of strategies and tactics, we have helped successfully position the Company as the developer of a unique cell therapy for safer, more effective stem cell transplants—and as an emerging leader in the broad CAR T cell and TCR immuno-oncology space.
Working with Bellicum since 2011, we have been instrumental in leveraging product milestones to generate investor and media interest in its highly differentiated, “controllable” cell therapies, resulting in press coverage in which Bellicum is discussed among the leaders in the space. We supported its successful financings and IPO, and continue to leverage corporate and product news flow to raise the company’s profile. BMC provides counsel on key corporate and clinical developments; drafts all PR materials, including press releases, talking points and QA; created Bellicum’s website and maintains it; and manages development of graphics and scientific illustrations.
BMC is involved in all aspects of public relations for Acceleron, a Cambridge biopharma developing protein therapeutics for hematologic, neuromuscular and other diseases. We provide strategic counsel on overall positioning, as well as messaging across corporate and product developments. We also deliver full editorial services for development of press releases, scripts, and slide presentations, as well as conceptual direction and execution of graphics, scientific illustration, photography and video.
BMC has introduced Acceleron to the broad trade and business media community, through outreach around major clinical milestones, and has established its social media programs. Our work has helped lead to a better understanding of Acceleron as an innovator with a rich pipeline of internally-discovered assets, including multiple late-stage, globally-partnered programs with blockbuster potential.
BMC created a strong corporate identity, positioning and materials, to enable this private, early-stage company to make a strong introduction to the investment community. Working with Geneius’ senior team, BMC developed messaging that clearly differentiates its technology and business strategy within the competitive immuno-oncology landscape.
We developed Geneius’ new logo and corporate branding, messaging and talking points, scientific illustrations of its technologies’ mechanism of action and manufacturing, and an investor deck that clearly articulates its unique value proposition.
BMC helps manage Castle’s corporate and product communications—using all forms of media and content strategies to gain exposure for an entirely new category of prognostic tools for staging cancers. We’ve conducted audience research and targeted messaging; developed a family of patient/doctor/payer awareness websites; created “explainer” animation; and orchestrated press and advocacy outreach.
Castle’s high-ranking web presence (1st page in search) and press coverage (NYT, CBS Evening News, biotech trades) solidified the position of its prognostic test for uveal melanoma as standard of care with 2/3rds market share. Press work and website/video/social media content for its cutaneous melanoma test has helped build awareness and traction for the product with dermatologists, patients and advocates. We continue to conduct media outreach around important milestones to help Castle realize its product potential—while improving patient care.
Arvinas is a private company with strong R&D and validating partnerships with Big Pharma for its targeted protein degradation therapies initially for cancers. BMC worked closely with senior management on its investor deck and an entirely new website to advance its public positioning from an early-stage research organization to a mainstream biopharma.
The website work involved written and visual story-telling, including development of a 3-D illustration of its unique mechanism, original photography, and the most current design and interactive features to fully illuminate the company’s promise and potential.
Heading into a U.S. IPO, Chinese biopharma BeiGene needed a website that would appeal to U.S. investors as well as its current Chinese investor base, prospective partners and employees, and a global patient and healthcare community.
BMC developed a dual-language website that differentiates the aspiring multi-national’s science and clinical development strategy within the immuno-oncology universe. Our team designed the look and feel, drafted the content to align with its S-1 prospectus, and built the website on a responsive, mobile-friendly platform. Throughout, we worked closely with BeiGene’s IR team to assure the site communicated the ambitious biotech’s mission and potential.